Revolution Medicines Inc
$ 103.24
-1.52%
25 Feb - close price
- Market Cap 20,265,716,000 USD
- Current Price $ 103.24
- High / Low $ 107.45 / 102.38
- Stock P/E N/A
- Book Value 8.42
- EPS -5.19
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -0.61 %
- 52 Week High 124.49
- 52 Week Low 29.17
About
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Analyst Target Price
$121.94
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-24 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-26 | 2023-11-06 | 2023-08-08 | 2023-05-08 | 2023-02-27 |
| Reported EPS | -1.61 | -1.31 | -1.13 | -1.12 | -0.94 | -0.81 | -0.7 | -1.14 | -0.99 | -0.92 | -0.72 | -0.63 |
| Estimated EPS | -1.41 | -1.12 | -0.75 | -0.9645 | -0.89 | -0.77 | -0.75 | -0.88 | -1.01 | -0.82 | -0.81 | -0.82 |
| Surprise | -0.2 | -0.19 | -0.38 | -0.1555 | -0.05 | -0.04 | 0.05 | -0.26 | 0.02 | -0.1 | 0.09 | 0.19 |
| Surprise Percentage | -14.1844% | -16.9643% | -50.6667% | -16.1223% | -5.618% | -5.1948% | 6.6667% | -29.5455% | 1.9802% | -12.1951% | 11.1111% | 23.1707% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.56 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RVMD
2026-02-24 23:52:27
This article provides an earnings preview for Revolution Medicines' Q4 2025 financial results. It is a brief overview focusing on the upcoming announcement.
2026-02-24 21:05:00
Revolution Medicines, Inc. announced that its CEO and Chairman, Mark A. Goldsmith, M.D., Ph.D., will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 9:50 a.m. ET. The company is a late-stage clinical oncology firm focused on developing targeted therapies for RAS-addicted cancers, with several RAS(ON) inhibitors in clinical development. A live webcast and archived replay of the event will be available on the company's investor relations website.
2026-02-24 13:52:27
Vanguard Group Inc. decreased its stake in Revolution Medicines (NASDAQ:RVMD) by 0.6% in the third quarter, selling 98,597 shares but still owning 15,663,094 shares valued at $731.5 million. Despite this, institutional investors collectively hold 94.34% of the company's stock, while insiders have been net sellers, offloading 113,792 shares in the past three months. Analysts mostly rate RVMD a "Buy," with an average target price of $78.94, which is below the stock's recent trading price of $103.69.
2026-02-24 06:52:27
JPMorgan has expressed high conviction in Revolution Medicines (RVMD) ahead of results from the RASolute 302 trial for pancreatic cancer, adding the stock to its "Positive Catalyst Watch" list. Analyst price targets have been significantly raised, with Oppenheimer even suggesting RVMD as an acquisition target. Revolution Medicines is a late-stage oncology company specializing in RAS-addicted cancers.
2026-02-23 10:20:08
Raiffeisen Bank International AG recently acquired 20,000 shares of Revolution Medicines, Inc. (RVMD) worth approximately $921,000 in the third quarter, establishing a new position. This comes despite significant insider selling totaling $15.24 million over the past 90 days. Analysts maintain a generally positive outlook on RVMD, with an average "Buy" rating and a price target of $78.94, while the stock currently trades around $101.83.
2026-02-23 10:01:24
JPMorgan Chase & Co. has reduced its stake in Revolution Medicines, Inc. (NASDAQ:RVMD) by 11.9%, selling 338,901 shares. Despite this, institutional investors collectively own 94.34% of the stock, while insiders have also been net sellers. Analysts maintain a "Buy" rating for RVMD with an average price target of $78.94.
